


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Lethe et al.
 Serial No. : 09/341,829
 Filed : October 18, 1999
 For : LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS
 Examiner : M. Davis
 Art Unit : 1642



CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 9th day of March, 2001.

Monica E. Zombori
 Monica E. Zombori

Commissioner for Patents
 Washington, DC 20231

STATEMENT PURSUANT TO 37 CFR 1.821(f) AND 37 CFR 1.825 (a) and (b)

This statement is made pursuant to 37 CFR 1.821 (f), and 37 CFR 1.825 (a) and (b). Applicants submit herewith a substitute copy of the written sequence listing and a computer readable diskette to comply with the sequence requirements.

Applicants' attorney states that the information recorded in computer readable form is identical to the written sequence listing and that neither the computer readable form nor the written sequence listing contain new matter.

Respectfully submitted,


John R. Van Amsterdam
 John R. Van Amsterdam, Reg. No. 40,212
 Wolf, Greenfield & Sacks, P.C.
 600 Atlantic Avenue
 Boston, MA 02210-2211
 (617)720-3500

Docket No. L0461/7066
 Dated: March 9, 2001
 x03/29/01

RECEIVED
 MAR 16 2001
 TECH CENTER 1600/2900

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7.

Other: _____

Applicant must provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 557-0400

RECEIVED
MAR 16 2001
TECH CENTER 4600/2900

Please return a copy of this notice with your response.